enoxaparin sodium / Generic mfg. - LARVOL DELTA

Low molecular weight heparin (LMWH) therapy guided by low placental growth factor (PlGF) in a diabetes-prevalent population: preliminary retrospective cohort. (PubMed, Pregnancy Hypertens) - "LMWH in low PlGF pregnancies, often complicated by diabetes, was associated with better glycemic control, improved placental function, and fewer SGA births. Findings support biomarker-guided trials of LMWH in thisgroup."

Journal • Retrospective data • Diabetes • Gestational Diabetes • Gynecology • Metabolic Disorders

Does Intravenous Tranexamic Acid Impact Risk of Venous Thromboembolism in Plastic & Reconstructive Surgery of the Head and Neck? (PubMed, Plast Reconstr Surg) - "IV TXA use was not associated with increased postoperative VTE risk in plastic and reconstructive surgery of the head and neck, supporting its continued use as a safe hemostatic adjunct in this patient population."

Journal • Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

AKI-ENOXA: Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration. (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Clinique Saint Pierre Ottignies

New trial • Critical care • Renal Disease

A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (clinicaltrials.gov) - P1 | N=186 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open

Bilateral rectus sheath hematoma following enoxaparin administration in a patient with extensive lower limb DVT: a rare complication. (PubMed, J Cardiothorac Surg) - "During the postoperative course, the patient developed a progressive infraumbilical abdominal wall swelling at the site of subcutaneous injections, later confirmed to be bilateral rectus sheath hematomas (RSH). This report highlights the importance of recognizing this rare complication in anticoagulated patients presenting with abdominal wall masses and anaemia."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

Venous Thromboembolism Chemoprophylaxis in Plastic Surgery: A Randomized Controlled Trial of Apixaban versus Enoxaparin. (PubMed, Plast Reconstr Surg) - No abstract available

Journal • Cardiovascular • Venous Thromboembolism

Pharmacological thromboprophylaxis in elderly medical inpatients: Lessons from a local audit in the era of NEJM Evidence. (PubMed, Intern Med J) - "Our findings suggest high guideline compliance and minimal bleeding associated with enoxaparin prophylaxis in this population. There is a need for simple and practical risk stratification tools with clear ambulation definitions, routine mobility assessments where appropriate and consideration of patient-accepted approaches such as oral thromboprophylaxis options."

Journal • Cardiovascular • Venous Thromboembolism

Case Report: A multidisciplinary, protocol-driven pathway from recurrent pregnancy loss to live birth in an anti-Ro/SSA-positive primary Sjögren's syndrome pregnancy with literature review. (PubMed, Front Immunol) - "A multidisciplinary protocol was implemented, including hydroxychloroquine 400 mg/day, methylprednisolone (initially 6 mg/day, briefly increased to 32 mg/day at 14-16 weeks, then tapered to 8 mg/day), low-dose aspirin 50 mg/day, and fondaparinux 2.5 mg/day from ovulation throughout pregnancy, along with scheduled intravenous immunoglobulin (IVIG; 20 g at 4, 6 + 6, and 8 + 2 weeks; followed by 20 g/day × 3 at 14, 18, and 22weeks)...Postpartum, the mother continued methylprednisolone 6 mg/day, hydroxychloroquine 400 mg daily, and enoxaparin 4,000 IU once daily for 4 weeks maintain disease suppression and thromboprophylaxis. In an anti-Ro/SSA-positive pregnancy at extreme risk, a prevention-first, protocol-driven approach-centered on hydroxychloroquine, judicious immunomodulation, and structured AV-interval surveillance-successfully averted CAVB and resulted in a pacemaker-free live birth. Minor cardiac lesions warrant ongoing follow-up;..."

Journal • Review • Cardiovascular • CNS Disorders • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sjogren's Syndrome

Simultaneous Intracranial and Spinal Hemorrhage Following Tenecteplase Thrombolysis for ST-Elevation Myocardial Infarction: A Case Report. (PubMed, Clin Case Rep) - "She was treated with oral aspirin, clopidogrel, atorvastatin, intravenous enoxaparin, tenecteplase (30 mg), and subcutaneous enoxaparin. In conclusion, tenecteplase can result in concurrent CNS hemorrhages even in the absence of vascular anomalies or coagulation defects. Clinicians should remain vigilant for both cranial and spinal hemorrhagic complications even with fibrin-specific agents like tenecteplase."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Myocardial Infarction • Pain

Prevention of Venous Thromboembolism in Patients with Intracerebral Hemorrhage (POWER) (ChiCTR) - P=N/A | N=600 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University

New trial • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Thrombosis • Venous Thromboembolism

A Randomized, Active-Controlled, Open-Label Clinical Study of Nafamostat Mesylate for Reducing Bleeding Risk in Maintenance Hemodialysis Patients at High Risk of Bleeding (ChiCTR) - P=N/A | N=338 | Not yet recruiting | Sponsor: The Seventh Affiliated Hospital Sun Yat-sen University; The Seventh Affiliated Hospital of Sun Yat-sen University

New trial • Renal Disease

A case of nonbacterial thrombotic endocarditis (ISC 2026) - "68 year-old woman with stage IV lung adenocarcionma on palliative afatinib developed dizziness, falls, abnormal speech, and left facial droop...She was started on anticoagulation with enoxaparin...Non-inferiority of direct oral anticoagulants (DOAC) to low molecular weight heparins in venous thromboembolism in patients with cancer have been demonstrated in randomized clinical trials. The lack of clinical trials specific to stroke and, in particular, enough experience in cases of probable valve thrombus limits the extrapolation from cancer-associated venous thromboembolism whether DOAC or low molecular weight heparins should be used."

Clinical • Brain Cancer • Cardiovascular • Ischemic stroke • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Venous Thromboembolism

Bilateral Posterior Circulation Strokes Due to Bilateral Bow Hunter's Syndrome (ISC 2026) - "Surgical fusion of the cervical vertebrae was considered, but because of the patient's age and size, the team elected for conservative management with aspirin and Lovenox and repeat imaging in one year. Recurrent, bilateral posterior circulation infarcts should prompt consideration of Bow Hunter's Syndrome. Dynamic imaging is typically required to make the diagnosis, most commonly DCA with head turn during the study."

Cardiovascular • Hematological Disorders • Hunter Syndrome • Ischemic stroke • Rheumatology • Vasculitis

Efficacy and safety of apixaban vs enoxaparin as prophylaxis in patients undergoing gynecological oncology surgery: A systematic review and meta-analysis. (ESGO 2026) - No abstract available

Retrospective data • Review • Surgery • Gynecologic Cancers • Oncology

CARE: Comparison of Apixaban Versus Enoxaparin (clinicaltrials.gov) - P=N/A | N=90 | Enrolling by invitation | Sponsor: Abramson Cancer Center at Penn Medicine | Trial completion date: Mar 2026 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Bladder Cancer • Cardiovascular • Genito-urinary Cancer • Oncology • Solid Tumor • Venous Thromboembolism

Evaluation of Prophylactic Enoxaparin Anti-Xa Levels in Individuals ≥150 kg. (PubMed, Thromb Haemost) - "One VTE event was observed. Our results suggest an appropriate empiric weight-based prophylactic enoxaparin dose for hospitalized patients ≥150 kg is 0.34 mg/kg twice daily."

Journal • Critical care

Accuracy of HAS-BLED and BleedMAP Scores in Predicting Postoperative Bleeding in Anticoagulated Patients Undergoing non-Cardiac Surgery. (PubMed, Clin Appl Thromb Hemost) - "The predictive performance of the two scores was compared using DeLong's method.ResultsAmong 591 patients who had previously received anticoagulation therapy, 84.9% received warfarin, 9.5% enoxaparin, and 5.6% direct oral anticoagulants. The two scores had no statistically significant difference (P = .13).ConclusionsThe HAS-BLED score showed limited discriminatory ability for postoperative bleeding in anticoagulated patients, though its negative predictive value was high. No significant difference in predictive performance was observed between the HAS-BLED and BleedMAP scores."

Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Venous Thromboembolism

The Cost-Effectiveness of Enoxaparin Compared with Aspirin for Thromboprophylaxis in Patients with Orthopaedic Trauma. (PubMed, J Bone Joint Surg Am) - "The findings suggest that enoxaparin is not cost-effective relative to aspirin for thromboprophylaxis in patients with orthopaedic trauma. The results support consideration of aspirin as a preferred agent in future guidelines, especially given the consistent patient preference for its oral administration."

HEOR • Journal • Cardiovascular • Hematological Disorders • Musculoskeletal Diseases • Orthopedics • Respiratory Diseases • Venous Thromboembolism

Safety Profile and Bleeding Complications of Fondaparinux Versus Enoxaparin in Non-ST Elevation Acute Coronary Syndrome. (PubMed, Cureus) - "Conclusions Fondaparinux demonstrates superior safety and effectiveness over enoxaparin in reducing bleeding complications and ischemic events among NSTE-ACS patients. These findings support its preferential use in resource-constrained clinical settings."

Journal • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Myocardial Infarction

PROPHYLACTIC ENOXAPARIN APPEARS SAFE IN A COHORT OF CRITICALLY ILL INFANTS WITH THREE OR MORE RISK FACTORS FOR HOSPITAL – ACQUIRED VENOUS THROMBOEMBOLISM (WRMC 2026) - No abstract available

Clinical • Cardiovascular • Venous Thromboembolism

Increased Prophylactic Enoxaparin Dosing is Associated With Improved Achievement of Target anti-Xa Levels; Implementation of the Western Trauma Association Venous-Thromboembolism Guidelines. (PubMed, J Surg Res) - "Utilization of a higher dose enoxaparin protocol for VTE prophylaxis has an improved likelihood of achieving plasma anti-Xa targets compared to standard dosing strategies, however, almost 23% of the patients were still underdosed. Increased enoxaparin dosing targeted to peak plasma anti-Xa levels and the impact on VTE reduction in severe burn and trauma patients should be further evaluated."

Journal • Cardiovascular • Mood Disorders • Thermal Injury • Venous Thromboembolism

PAI-1 Inhibition in experimental venous thrombosis. (PubMed, Phlebology) - "MDI-2268 1.5 mg/kg (Group 1), MDI-2268 3 mg/kg (Group 2), enoxaparin 7.3 mg/kg (Group 3), and MDI-2268 1.5 mg/kg plus enoxaparin 1.8 mg/kg (Group 4) were compared to the controls (sham surgery)...Thrombus weight and tail bleeding time were measured.ResultsTW was 6.9 ± 3.3 (p > .05), 5.5 ± 1.6 (p = .016), 3.8 ± 1.3 (p = .032), and 4.8 ± 2.4 mg (p = .016) for groups 1, 2, 3, and 4, respectively, compared to the controls. Bleeding time was not significantly affected by the MDI-2268.ConclusionsMDI-2268 is a novel pro-fibrinolytic agent that demonstrates strong antithrombotic properties without prolongation of bleeding time in this experimental model."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

A Break-Even Cost-Effectiveness Analysis for Venous Thromboembolism Prophylaxis in Achilles Tendon Repair Surgery (AAOS 2026) - "We found that aspirin 81 mg, aspirin 325 mg, and warfarin are cost effective for VTE chemoprophylaxis following surgery for Achilles tendon rupture. Enoxaparin and rivaroxaban are not cost effective."

Cost effectiveness • HEOR • Surgery • Cardiovascular • Venous Thromboembolism

Postoperative Enoxaparin Versus Aspirin in Tibial Nailing of Closed Tibial Fracture: Equivalent Effects in Preventing Deep Vein Thrombosis (AAOS 2026) - "Aspirin is as effective as enoxaparin in the prevention of deep vein thrombosis and pulmonary embolism in patients treated with intramedullary nailing of closed tibial fracture."

Cardiovascular • Hematological Disorders • Musculoskeletal Diseases • Orthopedics • Pulmonary Embolism • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Aspirin is Associated with a Lower Risk of Bleeding Complications than Enoxaparin in Aseptic Revision Total Hip Arthroplasty Patients (AAOS 2026) - "Aspirin chemoprophylaxis was associated with lower postoperative risk of DVT and fewer bleeding complications relative to enoxaparin."

Clinical • Orthopedics